Product review on the Anti-PD-L1 antibody atezolizumab
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 14, 期 2, 页码 269-276出版社
TAYLOR & FRANCIS INC
关键词
作者
我是这篇论文的作者
推荐
Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
Gautier Marcq, Luis Souhami, Fabio L. Cury, Afsar Salimi, Armen Aprikian, Simon Tanguay, Marie Vanhuyse, Raghu Rajan, Fadi Brimo, Jose Joao Mansure, Wassim Kassouf
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack
FRONTIERS IN IMMUNOLOGY (2023)
IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer
Wei Huang, Lizhen Zhu, Haoxuan Huang, Yuanyuan Li, Gongxian Wang, Cheng Zhang
BMC CANCER (2023)
Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer
Bufu Tang, Yajie Wang, Wangting Xu, Jinyu Zhu, Qiaoyou Weng, Weiqian Chen, Shiji Fang, Yang Yang, Rongfang Qiu, Minjiang Chen, Weiyang Mao, Min Xu, Zhongwei Zhao, Songhua Cai, Hongbing Zhang, Jiansong Ji
CANCER LETTERS (2023)
Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients
Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang, Shiqing Chen, Fengcai Wen, Hua Zhong, Baohui Han, Xueyan Zhang
FRONTIERS IN IMMUNOLOGY (2021)
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Jamie E. Chaft, Filiz Oezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michal Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric Toloza, Eric B. Haura, Ciaran J. McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone
NATURE MEDICINE (2022)
PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
Mohammed Safi, Hyat Ahmed, Mahmoud Al-Azab, Yun-long Xia, Xiu Shan, Mohammed Al-radhi, Abdullah Al-danakh, Abdullah Shopit, Jiwei Liu
JOURNAL OF ADVANCED RESEARCH (2021)
Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
Janina Swiderska, Mateusz Kozlowski, Sebastian Kwiatkowski, Aneta Cymbaluk-Ploska
CANCERS (2021)
Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer
Naoki Shijubou, Toshiyuki Sumi, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arlyn Apollo, Trey D. Durdin, Hong Truong, Jeffrey Kamradt, Maged Khalil, Bradley Lash, Irina Ostrovnaya, Asia S. McCoy, Grace Hettich, Ashley Regazzi, Marwah Jihad, Neha Ratna, Abigail Boswell, Kaitlyn Francese, Yuanquan Yang, Edmund Folefac, Harry W. Herr, S. Machele Donat, Eugene Pietzak, Eugene K. Cha, Timothy F. Donahue, Alvin C. Goh, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun V. Balar, Amir Mortazavi, Jonathan E. Rosenberg
JOURNAL OF CLINICAL ONCOLOGY (2022)
Biodistribution of 99mTc-PLA/PVA/Atezolizumab nanoparticles for non-small cell lung cancer diagnosis
Meliha Ekinci, Ralph Santos-Oliveira, Derya Ilem-Ozdemir
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2022)
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
Sreeram Ramagopalan, Alind Gupta, Paul Arora, Kristian Thorlund, Joshua Ray, Vivek Subbiah
JAMA NETWORK OPEN (2021)
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
Yingcheng Wang, Mingjun Rui, Lan Yang, Xintian Wang, Ye Shang, Aixia Ma, Hongchao Li
FRONTIERS IN PUBLIC HEALTH (2021)
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
EUROPEAN UROLOGY (2022)
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
Wenjie Liu, Gengwei Huo, Peng Chen
FRONTIERS IN IMMUNOLOGY (2022)
Oral Chemotherapy for Treatment of Lung Cancer
Sushma Jonna, Joshua E. Reuss, Chul Kim, Stephen V. Liu
FRONTIERS IN ONCOLOGY (2020)
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino, Jennifer G. Whisenant, Li-Ching Huang, Annalisa Trama, Valter Torri, Francesco Agustoni, Javier Baena, Giuseppe Banna, Rossana Berardi, Anna Cecilia Bettini, Emilio Bria, Matteo Brighenti, Jacques Cadranel, Alessandro De Toma, Claudio Chini, Alessio Cortellini, Enriqueta Felip, Giovanna Finocchiaro, Pilar Garrido, Carlo Genova, Raffaele Giusti, Vanesa Gregorc, Francesco Grossi, Federica Grosso, Salvatore Intagliata, Nicla La Verde, Stephen Liu, Julien Mazieres, Edoardo Mercadante, Olivier Michielin, Gabriele Minuti, Denis Moro-Sibilot, Giulia Pasello, Antonio Passaro, Vieri Scotti, Piergiorgio Solli, Elisa Stroppa, Marcello Tiseo, Giuseppe Viscardi, Luca Voltolini, Yi-Long Wu, Silvia Zai, Vera Pancaldi, Anne-Marie Dingemans, Jan Van Meerbeeck, Fabrice Barlesi, Heather Wakelee, Solange Peters, Leora Horn
LANCET ONCOLOGY (2020)
Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series
Jacques Cadranel, Stephen V. Liu, Michael Duruisseaux, Eva Branden, Yasushi Goto, Benjamin A. Weinberg, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Martin R. Jones, Alexander Drilon, Domenico Trombetta, Lucia Anna Muscarella, Khaled Tolba, Valerie Gounant, Agnieszka Cseh, Flavio Solca, Janessa J. Laskin, Daniel J. Renouf
ONCOLOGIST (2021)
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele
CLINICAL CANCER RESEARCH (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
JOURNAL OF CLINICAL ONCOLOGY (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G. Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Anna F. Farago, Chia-Chi Lin, Christos S. Karapetis, Yu-Chung Li, Bann-mo Day, David Chen, Timothy R. Wilson, Fabrice Barlesi
JOURNAL OF CLINICAL ONCOLOGY (2021)
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
Diego Cortinovis, Paolo Bidoli, Stefania Canova, Francesca Colonese, Maria Gemelli, Maria Luisa Lavitrano, Giuseppe Luigi Banna, Stephen V. Liu, Alessandro Morabito
CANCERS (2021)
NRG1 fusions: Biology to therapy
Stephen V. Liu
LUNG CANCER (2021)
Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
Joshua E. Reuss, Laura Gosa, Stephen Liu
CLINICAL LUNG CANCER (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
CLINICAL CANCER RESEARCH (2022)
Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting
Charu Aggarwal, Stephen V. Liu
JOURNAL OF CLINICAL ONCOLOGY (2023)
EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists
Stephen V. Liu, Ivy B. Elkins, Jill Feldman, Sarah B. Goldberg
ONCOLOGY AND THERAPY (2023)
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Stephen Liu, Tony S. K. Mok, Barzin Y. Nabet, Aaron S. Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smolin, Maximilian J. Hochmair, Marina C. Garassino, Carl M. Gay, John Heymach, Lauren A. Byers, Sivuonthanh Lam, Andres Cardona, Stefanie Morris, Leah Adler, David S. Shames, Martin Reck
LUNG CANCER (2023)
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
Xiuning Le, Lingzhi Hong, Chuck Hensel, Rongrong Chen, Haley Kemp, Niamh Coleman, Christine A. Ciunci, Stephen Liu, Marcelo Negrao, Jennifer Yen, Xuefeng Xia, Juergen Scheuenpflug, Christopher Stroh, Dilafruz Juraeva, Anne Tsao, David Hong, Victoria Raymond, Paul Paik, Jianjun Zhang, John Heymach
JCO PRECISION ONCOLOGY (2021)